HRTX News and Press, Heron Therapeutics Inc. From 04/30/21

ClearBridge is a leading global asset manager committed to active management. Research-based stock selection guides our investment approach, with our strategies reflecting the highest-conviction ideas of our portfolio managers. An accelerating rotation into value stocks in the small c...

Heron Therapeutics (HRTX): Q4 GAAP EPS of -$0.68 misses by $0.03.Revenue of $20.61M (-41.3% Y/Y) beats by $1.27M.Press Release For further details see: Heron Therapeutics EPS misses by $0.03, beats on revenue

Heron Therapeutics Announces Financial Results for the Three and Twelve Months Ended December 31, 2020 and Highlights Recent Corporate Updates PR Newswire SAN DIEGO , Feb. 24, 2021 /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotec...

We look at Heron Therapeutics for the first time since it received a CRL from the FDA late last Spring. The shares are up approximately one-third since we recommended to buy in that dip as the company has made progress on the marketing approval front. We take a look at recent even...

Heron Therapeutics ([[HRTX]] +0.1%) has announced that the results from an EPOCH 1 follow-on study evaluating HTX-011 in bunionectomy (surgery that corrects a deformed area of the foot near the big toe), have been published online, by the Journal of the American Podiatric Medical As...

SVB Leerink has downgraded Pacira BioSciences (PCRX) to Market Perform from Outperform citing competitive pressure on its lead product EXPAREL® (bupivacaine liposome injectable suspension).However, the price target was raised to $75 from $63 based on the results from a ‘physi...

Heron Therapeutics Announces Publication of Results from EPOCH 1 Follow-On Study of HTX-011 in Patients Undergoing Bunionectomy Surgery - 77% of Bunionectomy Patients Receiving HTX-011 Required No Opioids to Manage Their Postoperative Pain Through 72 Hours After Surgery and Cont...

Heron Therapeutics Highlights Progress in Pain Management and CINV Franchises and Announces New Development Program - Preliminary Full-Year 2020 Net Product Sales for CINV Franchise of Approximately $88.3 Million, versus Guidance of $85 Million - - Full-Year 2021 Net Product...

Heron Therapeutics has had a volatile year with the FDA, however, the 3rd quarter has mapped the recovery path and future for key labels. Zynrelef's approval in the EU across 27 member states confirms Heron's hypothesis in non-opioid analgesia for acute post-surgical applications. ...

Based on outcome and final minutes of a Type A End- of-Review meeting with FDA in September, Heron Therapeutics (HRTX) has refiled marketing application with the FDA seeking approval for HTX-011 for management of postoperative pain.The submission is classified as a Class 2...